Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11742860 | 0.87 | ADCY6 (0.56) | PNMTASIC3CD44MAOBDRD2 | |
| SCHEMBL30098006 | 0.86 | PNMT (0.52) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL21475687 | 0.86 | ADCY6 (0.57) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL25557986 | 0.86 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL18577020 | 0.86 | PNMT (0.52) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL20909780 | 0.86 | PNMT (0.52) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL20909783 | 0.86 | PNMT (0.52) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL20909790 | 0.86 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL14116965 | 0.86 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL25559173 | 0.86 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2CASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4543354-A | Anti-hypertensive 9-aminomethyl-benzo[f]quinoline-3,10-dione derivatives | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1985-09-24 | — | — | US | claimed |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220154232-A1 | Benzylisoquinoline Alkaloids (BIA) Producing Microbes, and Methods of Making and Using the Same | HERCULES CAPITAL, INC., AS AGENT | 2022-05-19 | — | — | US | disclosed |
| CN-113980826-A | Microorganisms producing benzylisoquinoline alkaloids and methods of making and using the same | 小利兰·斯坦福大学托管委员会 | 2022-01-28 | — | — | CN | disclosed |
| US-11214819-B2 | Benzylisoquinoline alkaloids (BIA) producing microbes, and methods of making and using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210363128-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-11-25 | — | — | US | disclosed |
| CN-105247038-B | Microorganisms that produce benzylisoquinoline alkaloids (BIAs) and methods of making and using the same | 小利兰·斯坦福大学托管委员会 | 2021-08-27 | — | — | CN | disclosed |
| EP-3865580-A1 | BENZYLISOQUINOLINE ALKALOIDS (BIA) PRODUCING MICROBES, AND METHODS OF MAKING AND USING THE SAME | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-08-18 | — | — | EP | disclosed |
| US-8940908-B2 | Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same | HANMI SCIENCE CO., LTD (KR) | 2015-01-27 | — | — | US | disclosed |
| WO-2014143744-A2 | BENZYLISOQUINOLINE ALKALOIDS (BIA) PRODUCING MICROBES, AND METHODS OF MAKING AND USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140273109-A1 | BENZYLISOQUINOLINE ALKALOIDS (BIA) PRODUCING MICROBES, AND METHODS OF MAKING AND USING THE SAME | HERCULES CAPITAL, INC., AS AGENT | 2014-09-18 | — | — | US | disclosed |
| US-20140148602-A1 | METHOD FOR PREPARING TETRAZOLE METHANESULFONIC ACID SALTS, AND NOVEL COMPOUND USED IN SAME | HANMI SCIENCE CO., LTD (KR) | 2014-05-29 | — | — | US | disclosed |
| US-8680277-B2 | Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same | HANMI SCIENCE CO., LTD (KR) | 2014-03-25 | — | — | US | disclosed |
| US-20130197227-A1 | METHOD OF PREPARING TETRABENAZINE AND DIHYDROTETRABENAZINE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-08-01 | — | — | US | disclosed |
| US-20120330020-A1 | METHOD FOR PREPARING TETRAZOLE METHANESULFONIC ACID SALTS, AND NOVEL COMPOUND USED IN SAME | HANMI SCIENCE CO., LTD (KR) | 2012-12-27 | — | — | US | disclosed |
| WO-2010075270-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | INCYTE CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20080176754-A1 | COMPOSITIONS AND METHODS FOR PRODUCING BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2008-07-24 | — | — | US | disclosed |
| WO-2008067070-A2 | COMPOSITIONS AND METHODS FOR PRODUCING BENZYLISOQUINOLINES ALKALOIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, YES1, MYC | PNMT 1339/4885ADRA2A 3705/4885ADRA2B 3748/4885 |
| US-20130197227-A1 | METHOD OF PREPARING TETRABENAZINE AND DIHYDROTETRABENAZINE | TET1, TET3, DNMT1 | PNMT 86/4885ADRA2A 827/4885ADRA2B 246/4885 |
| US-20140148602-A1 | METHOD FOR PREPARING TETRAZOLE METHANESULFONIC ACID SALTS, AND NOVEL COMPOUND USED IN SAME | TST, MPST, STS | PNMT 2060/4885ADRA2A 4362/4885ADRA2B 4040/4885 |
| US-20210363128-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, MYC, YES1 | PNMT 1280/4885ADRA2A 3763/4885ADRA2B 3814/4885 |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | PNMT 3528/4885ADRA2A 3895/4885ADRA2B 3806/4885 |
| US-20120330020-A1 | METHOD FOR PREPARING TETRAZOLE METHANESULFONIC ACID SALTS, AND NOVEL COMPOUND USED IN SAME | TST, MPST, STS | PNMT 2095/4885ADRA2A 4371/4885ADRA2B 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.